MedPath

VA Launches ProGRESS Study to Enhance Prostate Cancer Screening with Genetic Testing

The Department of Veterans Affairs (VA) has initiated the Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS) to investigate the potential of genetic testing in refining prostate cancer screening. This study aims to personalize screening recommendations based on individual genetic profiles, potentially improving screening efficacy and reducing unnecessary procedures.

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS), led by the Department of Veterans Affairs (VA), is pioneering research into the use of genetic testing to enhance prostate cancer screening. By analyzing genetic information from saliva samples, the study seeks to assess an individual's risk of developing prostate cancer, thereby tailoring screening recommendations to those at higher risk while minimizing unnecessary screenings for those at lower risk.
Why ProGRESS Matters to the VA
Prostate cancer screening, primarily through the PSA test, has been shown to slightly reduce mortality rates but also carries the risk of overdiagnosis and overtreatment. This has led to a lack of universal screening recommendations from major health organizations. The ProGRESS study aims to address this by leveraging genetic testing to provide a more precise screening approach, potentially revolutionizing how prostate cancer is detected and managed.
Study Recruitment and Participation
The ProGRESS study is recruiting Veterans aged 55-69 who have not previously undergone a prostate biopsy or MRI and have not been diagnosed with prostate cancer. Recruitment efforts include various outreach methods, aiming to enroll a diverse group of approximately 5,000 Veterans nationwide.
Consent and Biospecimen Collection
Participants can consent to the study through a web-based platform, with options for assistance and inquiries. They will provide a one-time saliva sample using a home-delivered kit, which is then analyzed for genetic risk factors related to prostate cancer.
Innovative Use of MVP Data
The study utilizes data from the Million Veteran Program (MVP) to develop the Prostate CAncer integrated Risk Evaluation (P-CARE) model. This model incorporates genetic variants, ancestry, and family history to estimate an individual's risk of developing metastatic prostate cancer.
Randomization and Intervention
Participants are randomized into two groups: one receiving personalized screening recommendations based on their genetic profile, and the other following standard screening practices. This approach aims to evaluate the effectiveness of precision screening in improving prostate cancer outcomes.
Follow-Up and Resources
All participants will engage in prostate health surveys over a period of up to 10 years, contributing valuable data to the study's findings. The ProGRESS study is a collaborative effort involving several institutions, including the Broad Institute and VA facilities, highlighting the VA's commitment to advancing prostate cancer research and care for Veterans.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Testing the ProGRESS of Precision Prostate Cancer Screening

A new precision risk screening tool for prostate cancer, developed by a team of VA, academic, and industry researchers, is being tested in a clinical trial named ProGRESS. This tool aims to improve the accuracy of prostate cancer screening by using individual risk prediction based on family history and genetic markers, potentially reducing unnecessary procedures and addressing health disparities.

UCSF Conducts Clinical Trials to Improve Prostate Cancer Treatment

UCSF is conducting clinical trials to explore the relationship between gene mutations and prostate cancer progression, aiming to improve treatment outcomes for men at high risk of biochemical recurrence. The study focuses on the effectiveness of combining darolutamide with androgen deprivation therapy (ADT) compared to placebo and ADT, using advanced imaging techniques to monitor cancer spread.

Stockholm3 Blood Test Shows Promise in Reducing Unnecessary Prostate Biopsies Across Diverse Ethnic Groups

A new blood test, Stockholm3, demonstrates potential in reducing unnecessary prostate biopsies while maintaining similar sensitivity to standard PSA screening.
The multi-center trial included over 2,100 patients across 17 U.S. clinical sites with diverse racial and ethnic backgrounds.

Self-Collected HPV Tests Poised to Reshape Cervical Cancer Screening

New guidelines propose self-collected HPV tests for cervical cancer screening, potentially increasing early detection and access to care.
A new study suggests HPV self-test results can stratify women into risk groups, optimizing follow-up and colposcopy referrals.

Pharmacogenetic Testing Could Benefit Most Cancer Patients, UK Study Finds

A UK study analyzing whole genome sequencing data reveals that 62.7% of cancer patients possess genetic changes increasing their risk of adverse reactions to common oncology drugs.
The research indicates that 6-10% of patients on drugs like capecitabine and fluorouracil could benefit from dose adjustments or alternative medications based on pharmacogenetic testing.

Genetic Test Predicts Docetaxel Benefit in Metastatic Prostate Cancer

A new genetic test, Decipher Prostate Genomic Classifier, can predict which metastatic prostate cancer patients will benefit from docetaxel therapy, according to the STAMPEDE trial.
High Decipher scores correlate with improved survival when docetaxel is added to androgen deprivation therapy (ADT) in metastatic prostate cancer patients.

Proteomic and Polygenic Profiling Enhances Colorectal Cancer Risk Stratification

A new study combines plasma proteomics and polygenic risk scores to improve colorectal cancer (CRC) risk prediction, potentially enabling personalized screening strategies.
The integrated model, incorporating protein biomarkers and genetic factors, demonstrates superior performance in identifying high-risk individuals compared to traditional risk assessments.

Saliva Test for Prostate Cancer Risk Could Save NHS £500 Million Annually

A new saliva test, PRODICT, can predict prostate cancer risk by analyzing DNA extracted from saliva, potentially enabling earlier diagnosis and treatment.
The NHS is launching a £2 million trial involving 1,000 men aged 40 to 55 to evaluate the test's effectiveness in identifying high-risk individuals.

Veracyte's Decipher Test Accurately Predicts Aggressive Prostate Cancer in Black Men

Veracyte's Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer in African American men, according to the VANDAAM trial.
The Decipher test, initially developed using primarily White American males, shows comparable accuracy in predicting metastasis in both African American and non-African American men.

Genetic Testing Improves Outcomes in Epilepsy Patients by Guiding Therapy

A new study reveals that genetic testing in epilepsy patients leads to changes in clinical management in approximately half of the cases.
Clinician-implemented changes based on genetic testing results in improved health outcomes for as many as 75% of patients.

Reference News

[1]
Prostate Cancer, Genetic Risk, and Equitable Screening Study ...
research.va.gov · Nov 15, 2024

The ProGRESS Study by the VA investigates genetic testing's role in enhancing prostate cancer screening. It uses saliva ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy